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Predictors of neck bleeding after eversion carotid
endarterectomy
Claudio Baracchini, MD,a Mario Gruppo, MD,b Franco Mazzalai, MD,b Renata Lorenzetti, MD,b
Giorgio Meneghetti MD,a and Enzo Ballotta, MD,b Padova, Italy
Objective:The aim of this study was to identify predictors for neck bleeding after eversion carotid endarterectomy (eCEA).
Methods: A prospectively compiled computerized database of all primary eCEAs performed at a tertiary referral center
between September 1998 and December 2009 was analyzed. The end point was any neck bleeding after eCEA. End point
predictors were identified by univariate analysis.
Results: Of 1458 eCEAs performed by the same surgeon on 1294 patients under general anesthesia with continuous
electroencephalographic monitoring and selective shunting, there were five major and three minor perioperative strokes
(0.5%), and no deaths. Neck bleeding after eCEA occurred in 120 cases (8.2%), of which 69 (4.7%) needed re-exploration.
Univariate analysis (odds ratio [95% confidence interval]) identified preoperative antiplatelet treatment with clopidogrel
(1.77 [1.20-2.62], P  .004), particularly when continued to the day before CEA (3.84 [2.01-7.33], P < .001), and
postoperative hypertension (9.44 [6.34-14.06], P < .001) as risk factors for neck bleeding in general and for neck
bleeding requiring re-exploration (4.50 [1.85-10.89], P .001; 15.27 [2.08-104.43], P .006, and 2.44 [1.12-5.30],
P  .02, respectively). An increased risk of neck bleeding in general was associated with clopidogrel plus acetylsalicylic
acid (12.00 [2.59-56.78], P  .005), acetylsalicylic acid alone (4.37 [1.99-9.57], P < .001), and ticlopidine (2.49
[1.10-5.63], P  .02) only when they were continued to the day before CEA. No neck bleeding was associated with
preoperative treatment with dipyridamole or warfarin, or no medication. No further complications occurred in the
patients who underwent re-exploration.
Conclusions: The results of this single-center university hospital study show that neck bleeding after CEA is relatively
common but is not associated with an increased risk of stroke or death. Preoperative treatment with clopidogrel,
particularly when it is continued to the day before surgery, and postoperative arterial hypertension seem to be associated
with a higher risk of neck bleeding after CEA, requiring re-exploration in most cases. Other antiplatelet agents appear to
be associated with an increased risk of postoperative neck bleeding only if they are continued to the day before CEA.
Larger studies are warranted to confirm our findings and prevent this feared surgical complication. (J Vasc Surg 2011;
54:699-705.)
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fCarotid endarterectomy (CEA) is the current stan-
dard care of proven efficacy in reducing the risk of stroke
in selected patients with symptomatic and asymptomatic
extracranial internal carotid artery (ICA) stenosis.1-4
Although stroke and death are the most important out-
come measures, other far-from-negligible complica-
tions contribute to the morbidity of CEA. An uncom-
mon but potentially life-threatening complication of
carotid revascularization is postoperative neck bleeding
that can cause respiratory failure and requires emergency
surgery.
In the North American Symptomatic Carotid Endar-
terectomy Trial (NASCET), wound bleeding after CEA
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doi:10.1016/j.jvs.2011.03.262ccurred in 5.5% of patients, making it a more frequent
omplication than major stroke and death (2.1%) or myo-
ardial infarction (0.9%).1 No information was available on
he outcome of theNASCET patients, but other series have
eported that as many as 50% of patients experiencing
leeding required re-exploration.5 The incidence of neck
leeding after CEA is not easy to ascertain reliably, how-
ver, because of substantial differences in its definition and
common tendency to report only bleeding needing sur-
ical evacuation, leading to lower reported rates of hemor-
hagic complications.
Preoperative antithrombotic medication (AM) with
ntiplatelet agents and anticoagulants has often been
mplicated as a risk factor for wound bleeding.6-15 Be-
ause there are increasingly broad indications in current
linical practice for antiplatelet agents as a primary or
econdary prevention of cerebrovascular, peripheral vas-
ular and coronary artery diseases, particularly after per-
utaneous coronary or peripheral artery procedures,16
nd for anticoagulants for atrial fibrillation, mechanical
rosthetic valves, reduced left ventricular systolic func-
ion, left ventricular apical thrombus, and prior deep
enous thrombosis or pulmonary embolism,17 most pa-
ients requiring CEA are expected to be taking some
orm of AM. The advisability of AM near the time of
EA is controversial: many surgeons recommend that
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September 2011700 Baracchini et alAM administration be continued to help prevent throm-
botic events, whereas others prefer to discontinue AM to
minimize the risk of perioperative bleeding.11,13,15
The aim of this study was to identify predictors of neck
bleeding after eversion CEA (eCEA) to prevent this surgi-
cal complication.
METHODS
This study was approved by the Institutional Review
Board of the University of Padua.
Patients. Demographic and clinical data were pro-
spectively entered into a computerized vascular surgery
registry for all patients who underwent CEA for symptom-
atic and asymptomatic ICA disease, based on the recom-
mendations of the NASCET1 and the Asymptomatic Ca-
rotid Atherosclerosis Study (ACAS),3 at our institution.
The registry was queried to identify patients who had neck
bleeding after CEA that did or did not require surgical
re-exploration, from September 1998 to December 2009.
The analysis excluded patients scheduled for CEA and
concomitant coronary artery bypass grafting or with asso-
ciated supra-aortic trunk lesions requiring concurrent sur-
gery and patients who required procedures for recurrent
disease.
The patients’ demographic and clinical data were re-
corded on a standardized form, including potential athero-
sclerotic risk factors, anatomic and clinical variables, preop-
erative medication, including antiplatelet agents or
anticoagulants, whether they were discontinued before sur-
gery, antihypertensive drugs, details of surgery, hospital
stay, and perioperative (30-day) outcomes.
Medication protocol. Our preoperative protocol for
symptomatic and asymptomatic patients includes the dis-
continuation of any type of preoperative antiplatelet agents,
including clopidogrel (75 mg/d); acetylsalicylic acid (ASA;
100 mg/d); dipyridamole (400 mg/d), ticlopidine (500
mg/d), or clopidogrel plus ASA, at least 8 days before
surgery. All patients who take oral anticoagulants discon-
tinue their warfarin medication 7 days before CEA to allow
the international normalized ratio to normalize. These
patients are transitioned to low-molecular-weight heparin,
which is stopped the night before CEA. In many cases, this
practice is only in part observed (patient’s omission, family
doctor’s suggestion, early admission), so AM is stopped
between days 2 and 8 before CEA, whereas in other cases
(patient’s omission, family doctor’s fear, transfer from neu-
rological wards) it is continued to the day before surgery.
The day after surgery, all patients restart their original
AM, and those who preoperatively were not taking AM
start with ASA (325 mg on the first day, followed by 100
mg daily). In this analysis, patients were arbitrarily stratified
according to whether or not they continued their AM to
the day before surgery.
Surgical procedures. All surgical procedures were
eCEAs performed by the same surgeon, with patients under
deep general anesthesia and with routine intraoperative
electroencephalographic (EEG) monitoring for a selective
use of intraluminal shunting. The technical details of the NCEA have been described elsewhere.18,19 Shunting de-
ended exclusively on EEG changes consistent with cere-
ral ischemia occurring during carotid cross-clamping, un-
elated to any bradycardia or arterial hypotension.20
atients were administered intravenous unfractionated
eparin (5000U) before ICA clamping, and heparinization
as never reversed with protamine.
Surgicel Fibrillar, an oxidized regenerated cellulose
Ethicon, Somerville, NJ) was routinely used on the suture
ine after the ICA was reimplanted in the common carotid
rtery. No completion angioscopy or imaging studies were
erformed. A single 14F suction drain was placed during
ound closure in all cases.
All patients were extubated immediately at the end of
he procedure andweremonitored in the recovery room for
hours, where their neurologic status was routinely as-
essed by a neurologist. Patients were transferred to the
eneral ward only if they remained neurologically and
emodynamically stable. All patients had invasive blood
ressure monitoring throughout the operation and while in
he surgical recovery unit. Antihypertensive medication was
iven in the recovery room if blood pressure rose 20%
bove the mean preoperative values or the systolic blood
ressure was 180 mm Hg.
Study end points. The study end points were any
linical signs of neck bleeding after CEA, warranting or not
arranting surgical re-exploration, including (1) expand-
ng wound hematoma, defined as postoperative neck swell-
ng with respiratory distress or airway obstruction requiring
racheal reintubation or wound re-exploration; (2) sudden
r excessive bleeding into the surgical drain with minimal
igns of hematoma formation, which required re-exploration;
nd (3) nonoperative hematoma, defined as neck swelling not
xpanding and stable in size on serial examination, and not
ausing airway or swallowing compromise, with no need for
e-exploration. Patients always underwent re-exploration
nder general anesthesia, and they were all transferred to
ntensive care, where the endotracheal tube was left in place
or at least 12 hours afterward.
Statistical analysis. All values are expressed as mean
tandard deviation. Continuous data were compared with
he Student t test (two-tailed) and categoric variables with
earson 2 test (two-tailed) or the Fisher exact test, as
ppropriate, calculating the odds ratio (OR) with 95%
onfidence intervals (CIs). Statistical significance was in-
erred for P  .05. Univariate analysis was used to deter-
ine the factors that might predict bleeding complications.
everal data items were analyzed by surgical procedures
ather than by patients because each perioperative outcome
as correlated with the surgical procedure and because
atients who underwent bilateral CEAs were exposed to
wice the risk of stroke, death, neck hemorrhage, or other
omplications.
ESULTS
A total of 1458 eCEA procedures were performed in
294 patients, of whom 164 had staged bilateral CEAs.
one of the CEAs were aborted or incomplete because of
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Volume 54, Number 3 Baracchini et al 701technical issues arising during surgery. Preoperative demo-
graphic data, risk factors, clinical signs, type of AM,
whether or not AM was discontinued before CEA, statin
medication, and other intraoperative variables, including
the side of the revascularized ICA, contralateral carotid
occlusion, incidence of shunting, perioperative blood loss,
carotid cross-clamping, and CEA procedure times are sum-
marized in Table I. Patients undergoing staged CEA pro-
cedures had the same AM for both procedures. Almost half
of eCEAs (48.6%) were performed with patients taking
statin medication. No ischemic or hemorrhagic cerebral
accidents or deaths occurred in the 8 days before CEA
Table I. Patients demographics and clinical details
Variables
No. (%),
Mean (range), or
Mean  SD
Patients, total 1294
Eversion CEA procedures 1458
Age, years 75.1 (39-96)
Male 885 (68.4)
Risk factors
Hypertension 787 (60.8)
Smoking 869 (67.1)
Diabetes 416 (32.1)
Hyperlipidemia 569 (43.9)
Cardiac disease 558 (43.1)
Chronic kidney disease 106 (8.2)
Pulmonary disease 207 (16.0)
Symptoms 953 (65.4)
Stroke 301 (20.6)
Transient ischemic attack 466 (32.0)
Amaurosis fugax 186 (12.8)
No symptoms 505 (34.6)
Antithrombotic medication
Clopidogrel 363 (24.9)
Continued to the day before CEA 110 (7.5)
Stopped before CEA 253 (17.4)
Clopidogrel plus ASA 86 (5.9)
Continued to the day before CEA 10 (0.7)
Stopped before CEA 76 (5.2)
ASA 387 (26.5)
Continued to the day before CEA 95 (6.5)
Stopped before CEA 292 (20.0)
Ticlopidine 273 (18.7)
Continued to the day before CEA 88 (6.0)
Stopped before CEA 185 (12.7)
Dipyridamole 81 (5.6)
Continued to the day before CEA 9 (0.6)
Stopped before CEA 72 (5.0)
Warfarin 102 (7.0)
No antithrombotic medication 166 (11.4)
Statin medication, n (%) 709 (48.6)
Intraoperative variables
Left side of operation 837 (57.4)
Contralateral carotid occlusion 203 (15.7)
Shunt placement 219 (15.0)
Blood loss, mL 60  25
Duration of CEA, minutes 74  6.9
Clamping time, minutes 22  8.8
ASA, Acetylsalicylic acid; CEA, carotid endarterectomy; SD, standard devi-
ation.among those patients who had discontinued their AM. wPerioperative (30-day) outcomes. Overall, 120
8.2%) neck hemorrhages occurred after CEA, and 69
4.7%) needed re-exploration (Table II). The surgeon’s
eport indicated the causes of the hematoma were bleeding
rising from the wound edges in 47 patients, venous oozing
rom the superficial layers of the cervicotomy in 10, and an
xcessive bleeding into the surgical drain in the remaining
2. All neck bleeding occurred within 1 to 8 hours after the
rocedure and was promptly treated surgically. No further
omplications occurred in the patients who required re-
xploration. Fifty-one cases of bleeding were conservatively
anaged: 43 neck swellings proved stable in size on serial
xamination and 8 large ecchymotic suffusions, extending
rom the neck to the upper third of the anterior thoracic
all, reabsorbed within 10 to 15 days after CEA. Overall,
ostoperative hypertension needing medication in the re-
overy room was recorded in 198 CEA procedures
13.6%), of which 62 (31.3%) involved neck bleeding after
EA and 44 (22.2%) required re-exploration.
Other perioperative outcomes and the mean hospital
tay are reported in Table II. Five major and three minor
erioperative strokes (0.5%) occurred in patients with no
eck bleeding after CEA. Two major strokes occurred in
atients who had discontinued their AM (ASA in both
ases) 5 and 6 days before surgery, three strokes occurred in
atients not taking AM, and three perioperative minor
trokes occurred in patients who had not discontinued their
M (clopidogrel in 2, and clopidogrel plus ASA in 1).
atients taking clopidogrel had a 1.8-fold and 2.6-fold risk
f neck hemorrhage compared with those taking ASA (OR,
.79; 95% CI, 1.08-2.95: P  .02) or warfarin (OR, 2.60;
5% CI, 1.03-6.55: P .04), respectively, whereas the risk
able II. Perioperative (30-day) outcomes
utcomes
No. (%) or
Mean  SD
atients 1294
EA procedures 1458
eck bleeding/hematoma 120 (8.2)
Re-exploration 69 (4.7)
ost-op hypertension in recovery 198 (13.6)
eath 0
troke 8 (0.5)
Major 5 (0.3)
Ipsilateral 4
Contralateral 1
Minor 3 (0.2)
Ipsilateral 1
Contralateral 2
ransient ischemic attack 38 (2.6)
Ipsilateral 23 (1.6)
Contralateral 15 (1.0)
erebral hemorrhage 0
yperperfusion syndrome 0
yocardial infarction 1 (0.06)
erve injury 59 (4.0)
ospital stay, days 4.6  2.8
EA, Carotid endarterectomy; SD, standard deviation.as comparable with all other types of AM (Table III).
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September 2011702 Baracchini et alPatients taking clopidogrel also had a 2.4-fold (OR, 2.47;
95% CI, 1.35-4.51; P  .003), 2.5-fold (OR, 2.54; 95%
CI, 1.28-5.03; P .007), and 8.5-fold (OR, 8.53; 95% CI,
1.45-49.86; P  .01) need for re-exploration compared
with patients taking ASA, ticlopidine, or dipyridamole,
respectively. Patients taking warfarin and those taking no
AM never needed re-exploration (Table III).
Univariate analysis identified clopidogrel (OR, 1.77;
95%CI, 1.20-2.62, P .004), particularly when continued
until the day before CEA (OR, 3.84; 95% CI, 2.01-7.33,
P .001), and postoperative hypertension (OR, 9.44; 95%
CI, 6.34-14.06; P  .001) as predictors of neck hemor-
rhage in general and neck bleeding requiring re-exploration
(OR, 4.50; 95%CI, 1.85-10.89, P .001; OR, 15.27; 95%
CI, 2.08-104.43, P  .006; and OR, 2.44; 95% CI, 1.12-
5.30; P  .02, respectively). Clopidogrel plus ASA (OR,
12.00; 95% CI, 2.29-56.78; P .005), ASA (OR, 4.37, CI
95% 1.99-9.57; P  .001), and ticlopidine (OR, 2.49, CI
95% 1.10-5.63; P .02) were associated with an increased
risk of neck hemorrhage in general only when they were
continued to the day before CEA. Preoperative dipyridam-
ole or warfarin treatment or no AM were not associated
with neck bleeding. None of the other variables considered,
including sex, baseline risk factors, presenting symptoms,
Table III. Risk of neck bleeding in general and neck bleed
antithrombotic medication (AM)
Variable
General
OR (95% CI)
Clopidogrel vs
Clopidogrel plus ASA 1.31 (0.60-2.84)
ASA 1.79 (1.08-2.95)
Ticlopidine 1.33 (0.79-2.23)
Dipyridamole 2.58 (0.93-7.11)
Warfarin 2.60 (1.03-6.55)
No AM 2.65 (1.23-5.68)
Clopidogrel plus ASA vs
ASA 1.36 (0.61-3.07)
Ticlopidine 1.01 (0.45-2.30)
Dipyridamole 1.97 (0.60-6.41)
Warfarin 2.01 (0.66-6.07)
No AM 2.02 (0.75-5.41)
ASA vs
Ticlopidine 1.27 (0.77-2.09)
Dipyridamole 1.44 (0.51-4.05)
Warfarin 1.45 (0.56-3.74)
No AM 1.48 (0.67-3.26)
Ticlopidine vs
Dipyridamole 1.94 (0.68-5.49)
Warfarin 1.95 (0.75-5.07)
No AM 1.99 (0.89-4.43)
Dipyridamole vs
Warfarin 0.99 (0.25-3.82)
No AM 1.02 (0.31-3-31)
Warfarin vs no AM 1.01 (0.34-3.05)
ASA, Acetylsalicylic acid; CEA, carotid endarterectomy; CI, confidence inte
aPatients taking warfarin and not taking antithrombotic medications never nstatin medication, and anatomic and intraoperative details, cere of predictive value for the risk of postoperative bleed-
ng (Table IV).
ISCUSSION
In this study of 1294 patients undergoing 1458
CEAs, the overall incidence of postoperative neck bleed-
ng was 8.2%, with a 4.7% rate of cases warranting surgical
e-exploration. Although a comparison with other series is
hallenging and should be drawn with caution because of the
ubstantial differences in the definition of neck hematoma and
he tendency ofmost authors to focusmainly on hemorrhagic
omplications requiring prompt re-exploration, our neck
leeding rates compared favorably with those reported in
revious investigations, ranging between 1.5% and
2%,6,7,9,10,21-27 and rising to 25% for radiographically
efined neck bleeding after CEA.8
The results of this study show that the risk of neck
leeding after CEA, requiring re-exploration in most cases,
as significantly higher in patients taking clopidogrel, par-
icularly if continued up to the day before CEA and in
atients with postoperative hypertension requiring medica-
ion in the recovery room. Patients taking clopidogrel plus
SA, ASA, or ticlopidine were more prone to hemorrhagic
requiring re-exploration related to preoperative
Neck bleeding
Requiring re-exploration
P OR (95% CI) P
.50 1.42 (0.59-3.40) .44
.02 2.47 (1.35-4.51) .003
.27 2.54 (1.28-5.03) .007
.07 8.53 (1.45-49.86) .01
.04 . . .a
.01 . . .a
.45 1.70 (0.68-4.45) .25
.96 1.78 (0.66-4.81) .26
.37 6.00 (0.91-38.60) .12
.22 . . .a
.16 . . .a
.35 1.02 (0.47-2.21) .94
.62 3.45 (0.57-20.61) .32
.45 . . .a
.34 . . .a
.25 3.35 (0.54-20.46) .31
.17 . . .a
.09 . . .a
.99 . . .a
.96 . . .a
.97 . . .a
R, odds ratio.
re-exploration.ing
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Volume 54, Number 3 Baracchini et al 703AM to the day before CEA. No other complications oc-
curred in the patients who had neck bleeding.
Our finding that taking clopidogrel before CEA corre-
lates significantly with neck bleeding is not new, although
Table IV. Univariate analysis of all considered variables
and neck bleeding after carotid endarterectomy (CEA)
Covariate
Univariate analysis
OR (95% CI) P
Male 0.84 (0.57-1.25) .40
Hypertension 1.21 (0.82-1.80) .32
Smoking 1.1 (0.73-1.65) .62
Diabetes mellitus 1.19 (0.81-1.77) .36
Hyperlipidemia 1.08 (0.74-1.58) .66
Cardiac disease 0.97 (0.66-1.41) .88
Chronic kidney disease 0.78 (0.37-1.63) .52
Pulmonary disease 1.2 (0.74-1.94) .46
Symptoms 1.2 (0.80-1.80) .41
Stroke 1.18 (0.76-1.84) .44
Transient ischemic attack 1.35 (0.92-1.99) .11
Amaurosis fugax 0.53 (0.26-1.05) .07
No symptoms 0.82 (0.55-1.23) .41
Antithrombotic medication
Clopidogrel 1.77 (1.20-2.62) .004
Continued to the day before
CEA 3.84 (2.01-7.33) .001
Bleeding with re-exploration 4.5 (1.85-10.89) .001
Continued to the day before
CEA 15.27 (2.08-104.43) .006
Clopidogrel plus ASA 1.15 (0.55-2.41) .70
Continued to the day before
CEA 12 (2.59-56.78) .005
Bleeding with re-exploration 1.95 (0.42-8.83) .70
Continued to the day before
CEA NA (0.60-NA) .42
ASA 0.78 (0.50-1.22) .29
Continued to the day before
CEA 4.37 (1.99-9.57) .001
Bleeding with re-exploration 0.87 (0.36-2.09) .82
Continued to the day before
CEA 2 (0.43-9.14) .45
Ticlopidine 1.15 (0.73-1.82) .53
Continued to the day before
CEA 2.49 (1.10-5.63) .02
Bleeding with re-exploration 0.39 (0.16-0.95) .04
Continued to the day before
CEA 4.8 (0.90-25.06) .11
Dipyridamole 0.56 (0.21-1.51) .40
Continued to the day before
CEA 2.87 (0.37-23.56) .38
Bleeding with re-exploration 0.19 (0.02-1.43) .15
Continued to the day before
CEA 0 (0.00-1.20) .25
Warfarin 0.55 (0.22-1.35) .20
No antithrombotic medication 0.53 (0.25-1.09) .09
Statin medication 0.85 (0.58-1.24) .40
Left side operation 1.31 (0.89-1.92) .17
Contralateral carotid occlusion 0.74 (0.43-1.30) .31
Shunt placement 1.3 (0.80-2.10) .28
Postoperative arterial hypertension 9.44 (6.34-14.06) .001
Bleeding with re-exploration 2.44 (1.12-5.30) .02
ASA, Acetylsalicylic acid; CI, confidence interval; NA, not available; OR,
odds ratio.the introduction of this medication for patients with estab- pished vascular disease is relatively recent. The relationship
etween clopidogrel and neck bleeding has been docu-
ented in recently published reports (Table V). All of the
bservational studies summarized in Table V considered a
elatively small number of patients taking AM, however, so
heir lack of statistical power prevents any definite conclu-
ion from being drawn on the relationship between bleed-
ng complications and AM. Similarly, no relationship
merged between AM and neck bleeding in two random-
zed studies in which low-dose clopidogrel23 and clopi-
ogrel plus ASA and dipyridamole29 were used to prevent
mbolization after CEA (a marker of thromboembolic
troke). Neither study was numerically powerful enough to
ssess bleeding complications, however.
The present study also showed that patients who con-
inued their AM (clopidogrel plus ASA, ASA, or ticlopi-
ine) until the day before CEA had an increased risk of neck
leeding compared with all other patients who discontin-
ed their AM or were not taking AM preoperatively; also of
ote is that no preoperative or perioperative adverse isch-
mic cerebral events developed in patients who were not
aking AM preoperatively.
Some surgeons prefer to discontinue AM before sur-
ery, fearing a risk of perioperative bleeding, whereas oth-
rs perform CEA in patients taking AM to prevent periop-
rative neurologic events, despite the higher incidence of
emorrhagic complications.11,13,15 Data to support either
pproach are limited and relate mainly to the literature on
ardiothoracic procedures (in favor of discontinuing treat-
ent),14 or orthopedic and ocular surgery (favoring con-
inued treatment).30-32
A 2007 audit on the United Kingdom community of
ascular surgeons investigated clopidogrel use at the time
f CEA and established that 52% of surgeons discontinue it
reoperatively, and 51% of them administer no alternative,
hereas 49% replace it with ASA.13 No data were available
n how many days before CEA the treatment was stopped.
A 2009 survey on the perioperative practices of Euro-
ean vascular surgeons found different attitudes, depend-
ng on the type of AM.15 Of the surgeons surveyed, 88%
ould not discontinue ASA for symptomatic or asymptom-
tic patients, whereas 12% would stop the treatment 1 to 7
ays before surgery.15 About half the surgeons would not
top clopidogrel for symptomatic and asymptomatic pa-
ients, but the other half would, at least a week before
urgery; surgeons were more likely to stop clopidogrel for
symptomatic than for symptomatic patients.15 However,
n a report on a small sample, there were no episodes of
eck bleeding, stroke, or death among 29 patients taking
o AM preoperatively.10 Because on the strength of avail-
ble data, it is still impossible to state the best way to
anage AM around the time of elective carotid surgery, it
s quite obvious that the only way to answer this question is
o pool prospective data so that sufficiently powerful results
an be achieved in a field where the number of events is very
mall.
The close relationship found in our analysis between
ostoperative arterial hypertension and neck bleeding con-
i
t
t
s
C
a
r
t
s
t
A
C
A
D
W
C
F
S
O
O
R
JOURNAL OF VASCULAR SURGERY
September 2011704 Baracchini et alfirms previous reports.6,7,26 Although patients requiring
reoperation for neck hematoma were reportedly hyperten-
sive before CEA and remained so after surgery,7,26 we
found that many of our patients with neck bleeding did not
have overt arterial hypertension before CEA. Hypertensive
swings and coughing at the time of extubation may also be
responsible for bleeding at the surgical site not seen at the
time of wound closure.
Because all CEA procedures in our series were eCEAs,
the relatively high 13.6% incidence of postoperative arterial
hypertension may relate to the possible interruption of
fibers in the carotid sinus nerve, despite every effort being
made to preserve the sinus nerves by transecting the ICA at
the carotid bulb just laterally to the carotid body. A signif-
icantly higher hypertension rate of 24% was documented
after eCEA in a retrospective analysis of 82 eCEAs com-
pared with 6% in 137 standard CEAs,33 consistent with
reports by other investigators who suggest that destroying
the baroceptor apparatus may result in postoperative
hypertension.34,35
Study limitation. This study has several limitations.
First, although data were prospectively collected, the anal-
ysis is retrospective in nature, limiting its strength. Second,
any study that only considers the results achieved by one
surgeon can hardly be used to draw any generalized con-
clusions, although the involvement of only one surgical
procedure (the eversion technique), one type of anesthesia
(general vs local), and one surgeon may help to reduce the
number of potential variables associated with hemorrhagic
complications after CEA. The surgeon’s reluctance to use
protamine for heparin reversal stems from its possible asso-
ciation with perioperative stroke,36 although recent studies
have reported that it reduces bleeding complications asso-
ciated with CEA without increasing the stroke risk.27
CONCLUSIONS
The results of our study have shown that neck bleeding
Table V. Studies examining the association between antip
after carotid endarterectomy (CEA)
First author Year Medication, patients
Rosembaum10 2010 Clopidogrel: 50; ASA: 171
Wait25 2010 Clopidogrel up to 5 days pre-CEA:
42
Clopidogrel up to 8 days pre-CEA:
58
Payne26 2010 AM in most of the patients: 448
Di Fiore25 2009 Clopidogrel; ASA
Fleming28 2009 Clopidogrel: 19; no clopidogrel: 81
Self 21 1999 ASA, ticlopidine, heparin,
Coumadin: 249
ASA, Acetylsalicylic acid; CI, confidence interval; OR, odds ratio.after CEA is relatively common but is not associated with anncreased risk of stroke or death. Preoperative antiplatelet
reatment with clopidogrel, particularly when continued to
he day before surgery, and postoperative hypertension
eem to be predictors of a higher risk of neck bleeding after
EA, which requires re-exploration in most cases. Other
ntiplatelet agents appear to be associated with an increased
isk of postoperative neck bleeding in general only when
hey are continued up to the day before CEA. Larger
tudies are warranted to confirm our findings and prevent
his feared surgical complication.
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